Physician profile
Edward Ventresca
NPI 1154395648
$2,675.63
in general payments reported to CMS, 2019-2025
16 companies · $298 in 2025
The $298 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $549 · 2020: $258 · 2021: $469 · 2022: $261 · 2023: $325 · 2024: $516 · 2025: $298.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $984 · Education: $155.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $983.59 |
| Education | $154.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $760.45 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $656.78 | 2020-2025 | Ofev |
| Astrazeneca Pharmaceuticals LP | $321.12 | 2019-2024 | Airsupra, Fasenra |
| Genzyme Corporation | $280.32 | 2022-2024 | |
| Grifols USA, LLC | $140.02 | 2021-2025 | Prolastin-C Liquid |
| Mallinckrodt Hospital Products INC. | $99.99 | 2021 | |
| Sanofi-Aventis U.S. LLC | $89.99 | 2025 | |
| Mylan Specialty L.P. | $88.22 | 2019-2024 | Yupelri |
| Insmed, INC. | $64.96 | 2023-2025 | Arikayce |
| Regeneron Healthcare Solutions, INC. | $54.63 | 2024-2025 | Dupixent |
| Verona Pharma, INC. | $37.56 | 2025 | Ohtuvayre |
| Takeda Pharmaceuticals U.S.A., INC. | $23.92 | 2023 | Glassia |
| Kci USA, INC. | $21.80 | 2023 | V.A.C.Ulta, V.A.C. Veraflo |
| La Jolla Pharmaceutical Company | $13.40 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $11.42 | 2021 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Philips North America LLC | $11.05 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edward Ventresca listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.